BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc. (Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/AVII

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity

AVI BioPharma Inc. (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA)-based drugs targeting a range of diseases. The Company has developed and optimized derivatives of its antisense chemistry (phosphorodiamidate morpholino oligomers (PMOs)) that can be designed to target disease mechanisms through mechanisms of action.   

Message Board Search for AVII: http://www.boardcentral.com/boards/AVII

In the report, the analyst notes:

"Revenues for the fourth quarter of 2009 were $5.1 million, compared to $5.5 million in the fourth quarter of 2008. Revenues for the full year ended December 31, 2009, were $17.6 million, compared to $21.3 million in the full year ended December 31, 2008, reflecting decreases in research contract revenues of $3.7 million.

"AVII recently announced that CureDuchenne and the Foundation to Eradicate Duchenne (FED) each awarded grants of $250,000 to AVII to support continued research and development of the Company's exon skipping drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. CureDuchenne and FED are U.S. not-for-profit foundations fully dedicated to supporting the research and development of a cure for DMD."